MA52011A - Vaccins peptidiques contre l'interleukine-31 - Google Patents

Vaccins peptidiques contre l'interleukine-31

Info

Publication number
MA52011A
MA52011A MA052011A MA52011A MA52011A MA 52011 A MA52011 A MA 52011A MA 052011 A MA052011 A MA 052011A MA 52011 A MA52011 A MA 52011A MA 52011 A MA52011 A MA 52011A
Authority
MA
Morocco
Prior art keywords
vaccines against
against interleukin
peptidic
peptidic vaccines
interleukin
Prior art date
Application number
MA052011A
Other languages
English (en)
Inventor
Gary Francis Bammert
Steven Alan Dunham
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA52011A publication Critical patent/MA52011A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
MA052011A 2018-03-16 2019-03-18 Vaccins peptidiques contre l'interleukine-31 MA52011A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862643921P 2018-03-16 2018-03-16

Publications (1)

Publication Number Publication Date
MA52011A true MA52011A (fr) 2021-01-20

Family

ID=66102208

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052011A MA52011A (fr) 2018-03-16 2019-03-18 Vaccins peptidiques contre l'interleukine-31

Country Status (11)

Country Link
US (3) US11433139B2 (fr)
EP (1) EP3765069A1 (fr)
JP (1) JP7497293B2 (fr)
KR (1) KR102672548B1 (fr)
CN (1) CN112135628B (fr)
AU (1) AU2019236328B2 (fr)
BR (1) BR112020017715A2 (fr)
CA (1) CA3093709C (fr)
MA (1) MA52011A (fr)
MX (2) MX2020009639A (fr)
WO (1) WO2019178601A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178601A1 (fr) * 2018-03-16 2019-09-19 Zoetis Services Llc Vaccins peptidiques contre l'interleukine-31
WO2021083766A1 (fr) * 2019-10-29 2021-05-06 Evax Ag Traitement du prurit chez les chevaux
WO2022109403A1 (fr) * 2020-11-23 2022-05-27 Scout Bio, Inc. Molécules de liaison à l'antigène et leurs utilisations
JP2024504194A (ja) * 2021-01-29 2024-01-30 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 自己寛容を破壊するためのワクチン組成物
AU2022223713A1 (en) 2021-02-22 2023-09-07 Zoetis Services Llc Horse il-31 induced pruritus model
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
AR133291A1 (es) * 2023-07-19 2025-09-17 Inst Pasteur De Montevideo Inmunización activa para el tratamiento de la dermatitis atópica
CN121360223A (zh) * 2024-07-19 2026-01-20 硕腾服务有限责任公司 流感疫苗
CN119462921B (zh) * 2024-11-12 2025-07-25 苏州恒贞生物科技有限公司 抗TNF-α抗体及其产品和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
PL200384B1 (pl) 1999-03-18 2008-12-31 Merck Patent Gmbh Polipeptyd blokujący adhezję płytek krwi, sposób jego otrzymywania, zastosowanie i zawierający go preparat farmaceutyczny
EP1130098A3 (fr) 2000-02-29 2003-09-10 Pfizer Products Inc. Osteorégulines mammifères
WO2001064754A1 (fr) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Anticorps a recombinaison genique et son fragment
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
AU2002359851A1 (en) 2001-12-21 2003-07-30 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20040176823A1 (en) 2003-02-25 2004-09-09 Island Tobin C. Acne treatment device and method
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
WO2006081573A2 (fr) 2005-01-28 2006-08-03 Zymogenetics, Inc. Preparations homogenes d'il-31
JP4927762B2 (ja) 2005-02-14 2012-05-09 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法
WO2006088855A1 (fr) 2005-02-14 2006-08-24 Zymogenetics, Inc. Méthodes de traitement d’affections de la peau en employant un antagoniste de il-31ra
WO2006104978A2 (fr) 2005-03-25 2006-10-05 Curagen Corporation Anticorps dirigés contre les antigènes majeurs de la ténascine
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP1777523A1 (fr) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode
AU2007249713A1 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
JP5230022B2 (ja) 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
CN103044550A (zh) 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
KR101603109B1 (ko) 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
EP2254592B1 (fr) 2008-02-28 2019-06-05 Dako Denmark A/S Multimères de mhc dans le diagnostic et le traitement de la borréliose
JP5450985B2 (ja) 2008-06-06 2014-03-26 三郎 齋藤 真核細胞において組換えタンパク質を細胞外に放出させるためのポリヌクレオチド
WO2009156960A2 (fr) 2008-06-27 2009-12-30 Pfizer Inc. Nouvelles compositions d'adjuvants
HRP20140395T1 (hr) 2008-08-20 2014-06-06 Zoetis Llc SPOJEVI PIROLO[2,3-d]PIRIMIDINA
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
WO2011065935A1 (fr) 2009-11-24 2011-06-03 Cornell University Procédés de production d'anticorps monoclonaux
US20120082644A1 (en) 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
WO2010117448A2 (fr) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Immunocytokines chimériques et leurs procédés d'utilisation
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
WO2012008037A1 (fr) 2010-07-15 2012-01-19 富士通株式会社 Appareil de décodage d'image animée, procédé de décodage d'image animée, appareil de codage d'image animée et procédé de codage d'image animée
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
WO2012068295A1 (fr) * 2010-11-16 2012-05-24 Selecta Biosciences, Inc. Oligonucléotides immunostimulants
WO2012116715A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des nouveaux-nés et des enfants en bas âge
WO2012116714A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des patients âgés
KR20150048905A (ko) 2011-06-28 2015-05-07 후루카와 덴키 고교 가부시키가이샤 전해 동박, 상기 전해 동박을 사용한 배선판 및 플렉서블 배선판
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR102257305B1 (ko) 2013-03-28 2021-05-28 더 유니버시티 오브 브리티쉬 콜롬비아 미세유동 장치 및 분비물의 다세포 검정법에서의 그의 사용 방법
KR20160010450A (ko) 2013-05-27 2016-01-27 프라운호퍼-게젤샤프트 추르 푀르데룽 데어 안제반텐 포르슝 에 파우 대식세포의 표적화된 조절
WO2015024669A1 (fr) 2013-08-21 2015-02-26 Curevac Gmbh Vaccin combiné
EP3142692B1 (fr) 2014-05-12 2019-05-01 Technion Research & Development Foundation Limited Compositions contenant l'il-31 et leurs utilisations
WO2015176162A1 (fr) 2014-05-22 2015-11-26 The University Of British Columbia Procédés permettant de déterminer des paires de chaînes des récepteurs de lymphocytes
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
WO2016065330A1 (fr) 2014-10-24 2016-04-28 Aladar Szalay Technique d'immunotherapie combinee pour le traitement du cancer
EP3792378B1 (fr) 2015-02-04 2023-08-23 The University of British Columbia Procédés et dispositifs pour l'analyse de particules
BR112018003967A2 (en) * 2015-09-08 2018-09-25 Universität Zürich Insect bite hypersensitivity treatment
CA2998390A1 (fr) 2015-09-28 2017-04-06 East Carolina University Adjuvants a base d'aluminium pour une vaccination tolerogene
CN109415416A (zh) 2016-03-04 2019-03-01 纽约大学 用于诱导抗肿瘤免疫的表达肿瘤相关抗原的多表位的病毒介体
AU2017256727B2 (en) 2016-04-27 2022-09-29 Saiba Animal Health Ag Treatment of canine atopic dermatitis
WO2018112363A1 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Méthodes de traitement du cancer à l'aide de parabacteroides
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2018156367A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
JP7365240B2 (ja) * 2017-03-07 2023-10-19 ウニヴェルズィテート チューリッヒ 馬の掻痒の治療
CN111148531A (zh) 2017-09-08 2020-05-12 伊夫罗生物科学公司 细菌胞外囊泡
CN111526881A (zh) 2017-09-08 2020-08-11 伊夫罗生物科学公司 来自普雷沃菌的胞外囊泡
WO2019075452A1 (fr) 2017-10-13 2019-04-18 Evelo Biosciences, Inc. Identification de bactéries pour la cancérothérapie
WO2019086694A1 (fr) * 2017-11-06 2019-05-09 Geert Mudde Vaccin et antigène il31
KR102745247B1 (ko) 2017-12-11 2024-12-23 유비아이 아이피 홀딩스 아토피성 피부염의 치료 및/또는 예방을 위한 il-31의 펩타이드 면역원 및 이의 제형물
WO2019178601A1 (fr) * 2018-03-16 2019-09-19 Zoetis Services Llc Vaccins peptidiques contre l'interleukine-31
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
EP3801604A1 (fr) 2018-05-28 2021-04-14 Evax AG Traitement de l'urticaire
CA3106796A1 (fr) 2018-07-19 2020-01-23 Oncohost Ltd Il-31 ameliorant l'efficacite d'une therapie cellulaire adoptive a base de macrophages contre le cancer
WO2020132275A1 (fr) 2018-12-19 2020-06-25 Ubi Ip Holdings Épitopes de lymphocytes t auxiliaires ubiquistes artificiels utilisés en tant que stimulateurs immunitaires pour immunogènes peptidiques synthétiques
AU2019406749A1 (en) 2018-12-20 2021-05-27 Saiba AG Virus-like particles of CMV modified by fusion

Also Published As

Publication number Publication date
CN112135628A (zh) 2020-12-25
MX2020009639A (es) 2021-01-08
MX2025011262A (es) 2025-10-01
US11433139B2 (en) 2022-09-06
US12343402B2 (en) 2025-07-01
US20220362391A1 (en) 2022-11-17
EP3765069A1 (fr) 2021-01-20
JP2021515800A (ja) 2021-06-24
WO2019178601A9 (fr) 2020-02-20
CA3093709A1 (fr) 2019-09-19
KR102672548B1 (ko) 2024-06-04
CA3093709C (fr) 2024-03-26
KR20200142010A (ko) 2020-12-21
AU2019236328B2 (en) 2025-10-09
AU2019236328A1 (en) 2020-09-10
RU2020129452A (ru) 2022-04-18
WO2019178601A1 (fr) 2019-09-19
BR112020017715A2 (pt) 2020-12-29
JP7497293B2 (ja) 2024-06-10
US20250325685A1 (en) 2025-10-23
US20190282704A1 (en) 2019-09-19
RU2020129452A3 (fr) 2022-04-18
CN112135628B (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
MA47677A (fr) Vaccins peptidiques
MA50813A (fr) Vaccins contre le virus d'epstein-barr
EP4028030A4 (fr) Vaccin contre le cytomégalovirus humain
EP4153730A4 (fr) Vaccins contre le sars-cov-2
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
EP3668522A4 (fr) Vaccins à base d'arnm efficaces
EP3364981A4 (fr) Vaccin contre le cytomégalovirus humain
EP3700565A4 (fr) Vaccins avec adjuvant
MA46584A (fr) Vaccin contre le cytomégalovirus humain
HRP20251619T1 (hr) Formulacije pneumokoknih konjugiranih cjepiva
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
MA53543A (fr) Vaccins peptidiques
IL277791A (en) HSP90 targeting conjugates and their formulations
MA52180A (fr) Vaccins thérapeutiques anti-abêta
IL284233A (en) Norovirus vaccine: formulations and methods
PL3784026T3 (pl) Dmuchawa
EP3638297A4 (fr) Vaccin bactérien
EP3178938A4 (fr) Vaccin dans un vecteur recombinant d'adénovirus aviaire de sérotype 9
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
EP3500280A4 (fr) Vaccins contre des virus
EP3781195A4 (fr) Antigènes vaccinaux chimériques contre l'anaplasmose
GB201910794D0 (en) Vaccine
EP3710041A4 (fr) Formulations peptidiques à libération prolongée
TN2020000219A1 (fr) Composes peptidiques multiepitopiques et vaccins contre la leishmaniose
EP3897691A4 (fr) Vaccins contenant de l'il-10 et leurs utilisations